GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gubra AS (OCSE:GUBRA) » Definitions » Change In Payables And Accrued Expense

Gubra AS (OCSE:GUBRA) Change In Payables And Accrued Expense : kr0.0 Mil (TTM As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Gubra AS Change In Payables And Accrued Expense?

Gubra AS's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2024 was kr0.0 Mil. It means Gubra AS's Accounts Payable & Accrued Expense stayed the same from Jun. 2024 to Dec. 2024 .

Gubra AS's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2024 was kr0.0 Mil. It means Gubra AS's Accounts Payable & Accrued Expense stayed the same from Dec. 2023 to Dec. 2024 .

Gubra AS Change In Payables And Accrued Expense Historical Data

The historical data trend for Gubra AS's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gubra AS Change In Payables And Accrued Expense Chart

Gubra AS Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Change In Payables And Accrued Expense
Get a 7-Day Free Trial - - - - -

Gubra AS Semi-Annual Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Change In Payables And Accrued Expense Get a 7-Day Free Trial Premium Member Only - - - - -

Gubra AS Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gubra AS Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Gubra AS's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Gubra AS Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gubra AS (OCSE:GUBRA) » Definitions » Change In Payables And Accrued Expense
Comparable Companies
OCSE:PEG OCSE:STRAP OCSE:BAVA OCSE:ZEAL VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX SMMT RPRX OCSE:GMAB XKRX:196170 INCY HKSE:02269
Traded in Other Exchanges
GUBRAc:UK PI3:Germany PI3:Germany
Address
Horsholm Kongevej 11B, Horsholm, DNK, 2970
Website
https://www.gubra.dk
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has three segments: Pre-clinical contract research (CRO), which derives maximum revenue; Discovery & Partnerships (D&P) Segment; and Gubra Green Segment. It derives maximum revenue from Pre-clinical contract research (CRO) segment. Geographically, the company operates in Europe, North America and Other regions.

Gubra AS Headlines

No Headlines